Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study

被引：0

作者：

Makoto Naganuma

Shinya Sugimoto

Tomohiro Fukuda

Keiichi Mitsuyama

Taku Kobayashi

Naoki Yoshimura

Hidehisa Ohi

Shinji Tanaka

Akira Andoh

Naoki Ohmiya

Keiichiro Saigusa

Takayuki Yamamoto

Yuichi Morohoshi

Hitoshi Ichikawa

Katsuyoshi Matsuoka

Tadakazu Hisamatsu

Kenji Watanabe

Shinta Mizuno

Takayuki Abe

Yasuo Suzuki

Takanori Kanai

机构：

[1] Keio University School of Medicine,Division of Gastroenterology and Hepatology, Department of Internal Medicine

[2] Kurume University School of Medicine,Division of Gastroenterology, Department of Medicine

[3] Kitasato University Kitasato Institute Hospital,Center for Advanced IBD Research and Treatment

[4] Tokyo Yamate Medical Center,Department of Internal Medicine, Division of IBD

[5] Imamura Hospital,Department of Gastroenterology

[6] Hiroshima University Hospital,Department of Endoscopy and Medicine

[7] Shiga University of Medical Science,Department of Medicine

[8] Fujita Health University School of Medicine,Department of Gastroenterology

[9] Tokyo Saiseikai Central Hospital,Department of Medicine

[10] Yokkaichi Hazu Medical Center,IBD Center

[11] Yokohama Municipal Citizen’s Hospital,Department of Medicine

[12] Tokai University Hachioji Hospital,Department of Gastroenterology

[13] Toho University Sakura Medical Center,Department of Gastroenterology

[14] Toho University Sakura Medical Center,Department of Internal Medicine

[15] Kyorin University School of Medicine,The Third Department of Internal Medicine

[16] Hyogo College of Medicine,Department of Intestinal Inflammation Research

[17] Keio University School of Medicine,Department of Preventive Medicine and Public Health, Biostatistics Unit at Clinical and Translational Research Center

[18] Toho University Sakura Medical Center,Inflammatory Bowel Disease Center

来源：

Journal of Gastroenterology | 2020年 / 55卷

关键词：

Ulcerative colitis; Indigo naturalis; Anti-TNFa treatment; Steroid dependent;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：169 / 180

页数：11

共 50 条

[31] Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Moderate orSevere Endoscopic Disease Activity at Baseline: A Post Hoc Analysis of the Phase 3 True North Study
Wolf, Douglas C.
Panaccione, Remo
Blumenstein, Irina
Long, Millie
Abraham, Bincy
Jain, Anjali
Memaj, Arteid
Wu, Chun
Hobbs, Vanessa
Harris, Sarah
Canavan, James B.
Peyrin-Biroulet, Laurent
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S514 - S515
[32] Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program
Rubin, David T.
Salese, Leonardo
Cohen, Mitchell
Kotze, Paulo G.
Woolcott, John C.
Su, Chinyu
Mundayat, Rajiv
Paulissen, Jerome
Torres, Joana
Long, Millie D.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2023, 16
[33] Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North Study
Khan, Nabeel
Irving, Peter
Blumenstein, Irina
Horst, Sara N.
Ahmad, Harris A.
Lawlor, Garrett
Hobbs, Vanessa
Jain, Anjali
Memaj, Arteid
Ananthakrishnan, Ashwin N.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S580 - S581
[34] Efficacy of Etrasimod in Patients With Ulcerative Colitis: A Post Hoc Analysis Based on Baseline Endoscopic Subscore
Yarur, Andres J.
Reinisch, Walter
Chang, Shannon
Gecse, Krisztina B.
Green, Jesse
Abbatemarco, Arcangelo M.
Wu, Joseph
Goetsch, Martina
Lazin, Krisztina
Pradeep, Gokul
Sands, Bruce E.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1025 - S1026
[35] Predicting late responders to filgotinib in patients with ulcerative colitis: a post hoc analysis of SELECTION and SELECTIONLTE
Beales, Ian
Matsuoka, Katsuyoshi
Lowenberg, Mark
Fumery, Mathurin
Takatori, Yoshie
Fujitani, Yasushi
Oortwijn, Alessandra
Faes, Margaux
Jamoul, Corinne
Hibi, Toshifumi
GUT, 2023, 72 (SUPPL_2) : A76 - A76
[36] Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: A post hoc analysis from the SELECTION study
Schreiber, Stefan
Feagan, Brian G.
Louis, Edouard
Hisamatsu, Tadakazu
Hibi, Toshifumi
Dron, Louis
Jamoul, Corinne
Patel, Haridarshan
Harris, Kristina
Taliadouros, Virginia
Oortwijn, Alessandra
Peyrin-Biroulet, Laurent
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024, 12 (09) : 1243 - 1255
[37] DOSE ESCALATION OF SUBCUTANEOUS VEDOLIZUMAB IN PATIENTS WITH ULCERATIVE COLITIS: A POST HOC ANALYSIS OF THE VISIBLE TRIAL DATA
Sandborn, William J.
Wolf, Douglas C.
D'Haens, Geert R.
Jansson, Johan P.
Chen, Jingjing
Uddin, Sharif M.
Candela, Ninfa
Lasch, Karen
Kisfalvi, Krisztina
GASTROENTEROLOGY, 2020, 158 (06) : S463 - S463
[38] Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data
Sandborn, W.
Wolf, D.
D'haens, G.
Jansson, J.
Chen, J.
Uddin, S.
Candela, N.
Lasch, K.
Kisfalvi, K.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S442 - S443
[39] Impact of time from transplant to treatment of patients with refractory cytomegalovirus infection: post hoc analysis of Phase 3 SOLTICE study
Chemaly, R.
Avery, R.
Dadwal, S.
Kamar, N.
Maertens, J.
Papanicolaou, G. A.
Witzke, O.
Gu, J.
Auciello, J.
SWISS MEDICAL WEEKLY, 2022, 152 : 8S - 8S
[40] Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology (vol 317,116895, 2023]
Jiang, Zhenhong
Sun, Yuting
Wu, Zhenhui
Tang, Mingxia
Ye, Anping
Tu, Bodan
Yi, Jianfeng
Xu, Huanhua
Gao, Yue
JOURNAL OF ETHNOPHARMACOLOGY, 2025, 337

← 1 2 3 4 5 →